Key clinical point: Outcomes are improved with adjuvant chemotherapy within 30 days of surgery, compared with beyond 30 days, in triple-negative breast cancer.
Major finding: 10-year overall survival was 82% with chemotherapy within 30 days of surgery versus 67.4%, 67.1%, and 65.1% with chemotherapy at 31-60, 61-90, and more than 91 days after surgery, respectively.
Study details: A retrospective review of 687 cases of TNBC.
Disclosures: Dr. Morante and Dr. Arteaga each reported having no relevant conflicts of interest to declare. Dr. Sparano has received consulting fees from Roche, Eli Lilly, Novartis, Celldex, AstraZeneca, Pfizer, and Adgero. He also has ownership interests with MetaStat.
Morante Z et al., SABCS 2018 Abstract GS2-05.
This Week's Must Reads
Must Reads in Breast Cancer
Therapeutic drug monitoring for tamoxifen not justified, Sanchez-Spitman A et al. J Clin Oncol. 2019 Jan 24. doi: 10.1200/JCO.18.00307.
With a positive sentinel node, RT better than surgery, Rutgers EJT et al. SABCS 2018, Abstract GS4-01